1. Pawlik TM. Intrahepatic cholangiocarcinoma: from diagnosis to treatment. Hepatobiliary Surg Nutr 2017;6(1):1. doi: 10.21037/hbsn.2017.01.04.
2. Shindoh J. Ablative therapies for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017;6(1):2-6. doi: 10.21037/hbsn.2016.09.07.
3. Savic LJ, Chapiro J, Geschwind JF. Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects. Hepatobiliary Surg Nutr 2017;6(1):7-21. doi: 10.21037/hbsn.2016.11.02.
4. Vijgen S, Terris B, Rubbia-Brandt L. Pathology of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017;6(1):22-34. doi: 10.21037/hbsn.2016.11.04.
5. Ronnekleiv-Kelly SM, Pawlik TM. Staging of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017;6(1):35-43. doi: 10.21037/hbsn.2016.10.02.
6. Levi Sandri GB, Ettorre GM, Colasanti M, De Werra E, Mascianà G, Ferraro D, Tortorelli G, Sciuto R, Lucatelli P, Pizzi G, Visco-Comandini U, Vennarecci G. Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation . Hepatobiliary Surg Nutr 2017;6(1):44-48. doi: 10.21037/hbsn.2017.01.08.
7. Lau WY. Commentary on the article entitled “hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation”. Hepatobiliary Surg Nutr 2017;6(1):49-51. doi: 10.21037/hbsn.2017.01.09.
8. Weigt J, Obst W, Malfertheiner P. The freedom of choice. Hepatobiliary Surg Nutr 2017;6(1):52-54. doi: 10.21037/hbsn.2017.01.13.
9. Li E, Liao W, Wu L. Effectiveness of covered metallic stents of benign biliary stricture resolution. Hepatobiliary Surg Nutr 2017;6(1):55-56. doi: 10.21037/hbsn.2017.02.01.
10. Ghosh S, Banerjee S. Whole-genome mutational analysis: cause and effect of noncoding and structural mutations in liver cancer. Hepatobiliary Surg Nutr 2017;6(1):57-59. doi: 10.21037/hbsn.2017.01.03.
11. Zhu C, Qian Q, Meng X, Zhao H. Comments on “JAMA PATIENT PAGE. Treatment of Liver Cancer”. Hepatobiliary Surg Nutr 2017;6(1):60-62. doi: 10.21037/hbsn.2016.12.08.
12. Xu MM, Brown E, Tyberg A, Kahaleh M. The evolving superiority of covered metallic stents for benign biliary strictures. Hepatobiliary Surg Nutr 2017;6(1):63-64. doi: 10.21037/hbsn.2017.01.10.
13. Lok HT, Chong CN, Chan AW, Fong KW, Cheung YS, Wong J, Lee KF, Lai PB. Primary hepatic gastrointestinal stromal tumor presented with rupture. Hepatobiliary Surg Nutr 2017;6(1):65-66. doi: 10.21037/hbsn.2017.01.11.
14. Fábrega-Foster K, Ghasabeh MA, Pawlik TM, Kamel IR. Multimodality imaging of intrahepatic cholangiocarcinoma Hepatobiliary Surg Nutr 2017;6(2):67-78. doi: 10.21037/hbsn.2016.12.10.
15. Wang K, Zhang H, Xia Y, Liu J, Shen F. Surgical options for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017;6(2):79-90. doi: 10.21037/hbsn.2017.01.06.
16. Bupathi M, Ahn DH, Bekaii-Saab T. Therapeutic options for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017;6(2):91-100. doi: 10.21037/hbsn.2016.12.12.
17. Gupta A, Dixon E. Epidemiology and risk factors: intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017;6(2):101-104. doi: 10.21037/hbsn.2017.01.02.
18. Koay EJ, Odisio BC, Javle M, Vauthey JN, Crane CH. Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments? Hepatobiliary Surg Nutr 2017;6(2):105-116. doi: 10.21037/hbsn.2017.01.16.
19. Sookoian S, Pirola CJ. Cell-free DNA methylation as liquid biopsy for the assessment of fibrosis in patients with nonalcoholic steatohepatitis: a gap between innovation and implementation Hepatobiliary Surg Nutr 2017;6(2):117-121. doi: 10.21037/hbsn.2017.01.07.
20. Teschke R, Schulze J. Green tea and the question of reduced liver cancer risk: the dawn of potential clinical relevance? Hepatobiliary Surg Nutr 2017;6(2):122-126. doi: 10.21037/hbsn.2017.03.03.
21. Bravi F, La Vecchia C, Turati F. Green tea and liver cancer. Hepatobiliary Surg Nutr 2017;6(2):127-129. doi: 10.21037/hbsn.2017.03.07.
22. Pirola CJ, Sookoian S. The natural history of nonalcoholic fatty liver disease: mortality rates and liver enzymes. Hepatobiliary Surg Nutr 2017;6(2):130-134. doi: 10.21037/hbsn.2017.03.02.
23. Loo SY, Chan WK. Emerging new standard for non-invasive assessment of liver disease mortality in non-alcoholic fatty liver disease. Hepatobiliary Surg Nutr 2017;6(2):135-137. doi: 10.21037/hbsn.2017.03.06.
24. Fodde R, Schmitt M, Schewe M, Augenlicht LH. Modelling western dietary habits in the mouse: easier said than done. Hepatobiliary Surg Nutr 2017;6(2):138-11. doi: 10.21037/hbsn.2017.01.20.
25. Hermann E, Foligne B. Healthy gut microbiota can resolve undernutrition. Hepatobiliary Surg Nutr 2017;6(2):141-143. doi: 10.21037/hbsn.2017.01.19.
26. Lu F, Soares KC, He J, Javed AA, Cameron JL, Rezaee N, Pawlik TM, Wolfgang CL, Weiss MJ. Neoadjuvant therapy prior to surgical resection for previously explored pancreatic cancer patients is associated with improved survival. Hepatobiliary Surg Nutr 2017;6(3):144-153. doi: 10.21037/hbsn.2016.08.06.
27. Ahmad A, Reha J, Saied A, Espat NJ, Somasundar P, Katz SC. Association of primary tumor lymph node ratio with burden of liver metastases and survival in stage IV colorectal cancer.. Hepatobiliary Surg Nutr 2017;6(3):154-161. doi: 10.21037/hbsn.2016.08.08.
28. Wanis KN, Pineda-Solis K, Tun-Abraham ME, Yeoman J, Welch S, Vogt K, Van Koughnett JA, Ott M, Hernandez-Alejandro R. Management of colorectal cancer with synchronous liver metastases: impact of multidisciplinary case conference review. . Hepatobiliary Surg Nutr 2017;6(3):162-169. doi: 10.21037/hbsn.2017.01.01.
29. Valderrama-Treviño AI, Granados-Romero JJ, Espejel-Deloiza M, Chernitzky-Camaño J, Barrera Mera B, Estrada-Mata AG, Ceballos-Villalva JC, Acuña Campos J, Argüero-Sánchez R. Updates in Mirizzi syndrome. Hepatobiliary Surg Nutr 2017;6(3):170-178. doi: 10.21037/hbsn.2016.11.01.
30. Chin KM, Ho WY, Lim KH, Chung YF, Lee SY. Follicular dendritic cell sarcoma of the liver with metachronous small bowel and splenic metastases: a case report and literature review. Hepatobiliary Surg Nutr 2017;6(3):179-189. doi: 10.21037/hbsn.2016.08.04.
31. Johnson AM, DePaolo RW. Window-of-opportunity: neonatal gut microbiota and atopy. Hepatobiliary Surg Nutr 2017;6(3):190-192. doi: 10.21037/hbsn.2017.03.05.
32. Pagano D, Barbieri L, Seidita A, Gruttadauria S. Importance of sarcopenia parameter changes after living donor liver transplantatio . Hepatobiliary Surg Nutr 2017;6(3):193-195. doi: 10.21037/hbsn.2017.03.11.
33. Uchiyama H. Sarcopenia in liver transplant recipients: its relevance to peritransplant morbidity and mortality. Hepatobiliary Surg Nutr 2017;6(3):196-199. doi: 10.21037/hbsn.2017.03.10.
34. Moris D, Burkhart RA, Beal EW, Pawlik TM. Laparoscopic hepatectomy for hepatocellular carcinoma: are oncologic outcomes truly superior to an open approach? Hepatobiliary Surg Nutr 2017;6(3):200-202. doi: 10.21037/hbsn.2017.03.09.
35. Hibi T, Kitagawa Y. Laparoscopic liver resection for hepatocellular carcinoma in cirrhotic patients: a potential game changer toward global standardization of care. Hepatobiliary Surg Nutr 2017;6(3):203-204. doi: 10.21037/hbsn.2017.04.02.
36. Huang J, Sang X, Zhong S. A call for scientific integrity. Hepatobiliary Surg Nutr 2017;6(3):205-206. doi: 10.21037/hbsn.2017.05.08.
37. Sommacale D, Rhaiem R, Piardi T, Cagniet A, Kianmanesh R.
38. Cusumano C, De Carlis L. Multinodular liver involvement in Abernethy syndrome. Hepatobiliary Surg Nutr 2017;6(3):210-211. doi: 10.21037/hbsn.2017.03.08.
39. Huang J. The “Chinese Mode” of organ donation and transplantation. Hepatobiliary Surg Nutr 2017;6(4):212-214. doi: 10.21037/hbsn.2017.07.08
40. Editorial Office. Hepatobiliary Surgery and Nutrition is indexed by SCIE: a tremendous step forward. Hepatobiliary Surg Nutr 2017;6(4):215-218. doi: 10.21037/hbsn.2017.06.08
41. Fong Y, Woo Y, Giulianotti PC. Robotic surgery: the promise and finally the progress. Hepatobiliary Surg Nutr 2017;6(4):219-221. doi: 10.21037/hbsn.2017.04.04
42. Lai EC, Tang CN. Training robotic hepatectomy: the Hong Kong experience and perspective Hepatobiliary Surg Nutr 2017;6(4):222-229. doi: 10.21037/hbsn.2017.01.21
43. Choi GH, Chong JU, Han DH, Choi JS, Lee WJ. Robotic hepatectomy: the Korean experience and perspective. Hepatobiliary Surg Nutr 2017;6(4):230-238. doi: 10.21037/hbsn.2017.01.14
44. Nota CL, Rinkes IH, Hagendoorn J. Setting up a robotic hepatectomy program: a Western-European experience and perspective. Hepatobiliary Surg Nutr 2017;6(4):239-245. doi: 10.21037/hbsn.2016.12.05
45. Patti JC, Ore AS, Barrows C, Velanovich V, Moser AJ. Value-based assessment of robotic pancreas and liver surgery. Hepatobiliary Surg Nutr 2017;6(4):246-257. doi: 10.21037/hbsn.2017.02.04
46. Umemura A, Takahara T, Nitta H, Hasegawa Y, Sasaki A. Is sarcopenia a prognostic factor after living donor liver transplantation?. Hepatobiliary Surg Nutr 2017;6(4):258-259. doi: 10.21037/hbsn.2017.03.13
47. Brustia R, Scatton O. Pretransplant sarcopenia: suffer or fight? Hepatobiliary Surg Nutr 2017;6(4):260-263. doi: 10.21037/hbsn.2017.03.15
48. Fukui H. A new link between innate immunity and hepatic metabolism: attractive unknown place to visit. Hepatobiliary Surg Nutr 2017;6(4):264-267. doi: 10.21037/hbsn.2017.04.01
49. Obuch JC, Wagh MS. Endoscopic therapy for benign biliary strictures: evaluation of metal vs. plastic biliary stents. Hepatobiliary Surg Nutr 2017;6(4):268-271. doi: 10.21037/hbsn.2017.05.04
50. Cucchetti A, Serenari M. Resection or ablation for very early hepatocellular carcinoma and the fundamental problem of causal inference. Hepatobiliary Surg Nutr 2017;6(4):272-273. doi: 10.21037/hbsn.2017.05.03
51. Brown CR, MacLachlan JH, Cowie BC. Addressing the increasing global burden of viral hepatitis. Hepatobiliary Surg Nutr 2017;6(4):274-276. doi: 10.21037/hbsn.2017.05.02
52. Franco E, Pettinicchio V, Zorzoli E. The evolution of the burden of viral hepatitis from 1990 to 2013: still an open challenge to global public health policy. Hepatobiliary Surg Nutr 2017;6(4):277-279. doi: 10.21037/hbsn.2017.05.01
53. Tanaka K. Resection versus transplantation for hepatocellular carcinoma exceeding Milan criteria within increasing donor shortage. . Hepatobiliary Surg Nutr 2017;6(4):280-283. doi: 10.21037/hbsn.2017.03.14
54. Kays JK, Milgrom DP, Koniaris LG. Resection or transplantation for hepatocellular carcinoma: is the decision clear for patients beyond Milan criteria? Hepatobiliary Surg Nutr 2017;6(4):284-286. doi: 10.21037/hbsn.2017.04.03
55. Zaydfudim VM, Chapman WC, Nagorney DM. Challenges in patient selection for liver resection or transplantation in patients with hepatocellular carcinoma beyond Milan criteria. Hepatobiliary Surg Nutr 2017;6(4):287-289. doi: 10.21037/hbsn.2017.07.04
56. Singh P, Kumar S, Chandra A. Persistent bronchobiliary fistula managed by endoscopic biliary stenting. Hepatobiliary Surg Nutr 2017;6(4):290-291. doi: 10.21037/hbsn.2017.05.09
57. Chen PD, Wu CY, Wu YM. Use of robotics in liver donor right hepatectomy. Hepatobiliary Surg Nutr 2017;6(5):292-296. doi: 10.21037/hbsn.2017.01.17
58. Warner SG, Jutric Z, Nisimova L, Fong Y. Early recovery pathway for hepatectomy: data-driven liver resection care and recovery. Hepatobiliary Surg Nutr 2017;6(5):297-311. doi: 10.21037/hbsn.2017.01.18
59. Wong FC, Lai EC, Chung DT, Tang CN. Robotic transduodenal excision of ampullary tumour. Hepatobiliary Surg Nutr 2017;6(5):312-316. doi: 10.21037/hbsn.2016.12.04
60. McCoy SM, Campbell KL, Lassemillante AC, Wallen MP, Fawcett J, Jarrett M, Macdonald GA, Hickman IJ. Changes in dietary patterns and body composition within 12 months of liver transplantation Hepatobiliary Surg Nutr 2017;6(5):317-326. doi: 10.21037/hbsn.2017.01.12
61. Paik KY. Appropriate surgical therapy for patients with hepatocellular carcinoma beyond Milan criteria. Hepatobiliary Surg Nutr 2017;6(5):327-328. doi: 10.21037/hbsn.2017.05.06
62. Garcia C, Acosta LF, Gedaly R. Expanding the boundaries of Milan Hepatobiliary Surg Nutr 2017;6(5):329-331. doi: 10.21037/hbsn.2017.05.11
63. Akamatsu N, Sakamoto Y, Hasegawa K. Liver transplantation for the solitary intrahepatic cholangiocarcinoma less than 2 cm in diameter. Hepatobiliary Surg Nutr 2017;6(5):332-334. doi: 10.21037/hbsn.2017.05.10
64. Petrowsky H. Should we expand liver transplant criteria to cirrhotic patients with intrahepatic cholangiocarcinoma? Hepatobiliary Surg Nutr 2017;6(5):335-338. doi: 10.21037/hbsn.2017.07.01
65. Colombo M, Torzilli G. Expanding transplantation of patients with a liver cancer without harming allocation: a priority in the era of scarce donation. Hepatobiliary Surg Nutr 2017;6(5):339-341. doi: 10.21037/hbsn.2017.05.13
66. Rauchfuß F, Dondorf F, Fahrner R, Tautenhahn HM, Ardelt M, Settmacher U. Searching the ideal hepatocellular carcinoma patient for liver transplantation: are the Toronto criteria a step in the right direction? Hepatobiliary Surg Nutr 2017;6(5):342-343. doi: 10.21037/hbsn.2017.05.14
67. Moro M, Casanova M, Roz L. Patient-derived xenografts, a multi-faceted in vivo model enlightening research on rare liver cancer biology Hepatobiliary Surg Nutr 2017;6(5):344-346. doi: 10.21037/hbsn.2017.06.0
68. Ilmer M, Berger M. Avatars to personalized medicine: of mice and men. Hepatobiliary Surg Nutr 2017;6(5):347-349. doi: 10.21037/hbsn.2017.06.05
69. Oliveira CP, Stefano JT, Carrilho FJ. Clinical patterns of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD): a multicenter prospective study. Hepatobiliary Surg Nutr 2017;6(5):350-352. doi: 10.21037/hbsn.2017.06.06
70. Elcioglu ZC, Reeves HL. NAFLD—which patients should have hepatocellular carcinoma surveillance? Hepatobiliary Surg Nutr 2017;6(5):353-355. doi: 10.21037/hbsn.2017.06.04
71. Otsuka Y, Kaneko H. Laparoscopic liver resection in the treatment of HCC with liver cirrhosis: would it provide superiority to conventional open hepatectomy? Hepatobiliary Surg Nutr 2017;6(5):356-358. doi: 10.21037/hbsn.2017.06.02
72. Dewdney B, Hebbard L. Implementing genetic screening for the management of hepatic disease. Hepatobiliary Surg Nutr 2017;6(5):359-362. doi: 10.21037/hbsn.2017.07.06
73. Kumar P, Kumar S, Chandra A. Acute on chronic pancreatitis in a young female. Hepatobiliary Surg Nutr 2017;6(5):363-364. doi: 10.21037/hbsn.2017.06.07
74. Jiang C, Li N. Prof. Tilman Sauerbruch: patients with HCC may be benefit from statins. Hepatobiliary Surg Nutr 2017;6(5):365-366. doi: 10.21037/hbsn.2017.08.01
75. Hammad A, Kaido T, Hamaguchi Y, Okumura S, Kobayashi A, Shirai H, Kamo N, Yagi S, Uemoto S. Impact of sarcopenic overweight on the outcomes after living donor liver transplantation. Hepatobiliary Surg Nutr 2017;6(6):367-378. doi: 10.21037/hbsn.2017.02.02
76. Huisman F, Cieslak KP, van Lienden KP, Bennink RJ, van Gulik TM. Liver related complications in unresectable disease after portal vein embolization. Hepatobiliary Surg Nutr 2017;6(6):379-386. doi: 10.21037/hbsn.2017.02.03
77. Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. Hepatobiliary Surg Nutr 2017;6(6):387-396. doi: 10.21037/hbsn.2017.11.01
78. Wang SE, Chen SC, Shyr BU, Shyr YM. Robotic assisted excision of type I choledochal cyst with Roux-en-y hepaticojejunostomy reconstruction. Hepatobiliary Surg Nutr 2017;6(6):397-400. doi: 10.21037/hbsn.2017.01.15
79. Issa D, Alkhouri N. Nonalcoholic fatty liver disease and hepatocellular carcinoma: new insights on presentation and natural history. Hepatobiliary Surg Nutr 2017;6(6):401-403. doi: 10.21037/hbsn.2017.07.07
80. Bévant K, Coulouarn C. Landscape of genomic alterations in hepatocellular carcinoma: current knowledge and perspectives for targeted therapies. Hepatobiliary Surg Nutr 2017;6(6):404-407. doi: 10.21037/hbsn.2017.10.02
81. BYoon SB, Chang JH. Extracellular vesicles in bile: a game changer in the diagnosis of indeterminate biliary stenoses?. Hepatobiliary Surg Nutr 2017;6(6):408-410. doi: 10.21037/hbsn.2017.10.01
82. Liu F, Ma WJ, Hu HJ, Regmi P, Wang JK, Li FY. The puzzle and challenge in the treatment of an intraoperative margin-positive proximal bile duct in hilar cholangiocarcinom. Hepatobiliary Surg Nutr 2017;6(6):411-413. doi: 10.21037/hbsn.2017.11.05
83. Marí M, Morales A. Bone morphogenetic protein-9/activin-like kinase 1 axis a new target for hepatic regeneration and fibrosis treatment in liver injury. Hepatobiliary Surg Nutr 2017;6(6):414-416. doi: 10.21037/hbsn.2017.11.02
84. Tajiri K, Shimizu Y. Gut bacteria may control development of hepatocellular carcinoma. Hepatobiliary Surg Nutr 2017;6(6):417-419. doi: 10.21037/hbsn.2017.07.05
85. Miura K. The day will come to treat HCC in a drugstore? Hepatobiliary Surg Nutr 2017;6(6):420-423. doi: 10.21037/hbsn.2017.07.09
86. Fukui H. Improve gut microbiome: a new horizon of cancer therapy. Hepatobiliary Surg Nutr 2017;6(6):424-428. doi: 10.21037/hbsn.2017.08.04
87. Bengmark S. Choose right carbohydrates and right fats (RCRF) - keys to optimal health. Hepatobiliary Surg Nutr 2017;6(6):429-433. doi: 10.21037/hbsn.2017.12.03
88. Kaido T, Hamaguchi Y, Uemoto S. Sarcopenia plays a crucial role in liver transplantation. Hepatobiliary Surg Nutr 2017;6(6):434-436. doi: 10.21037/hbsn.2017.08.05
89. Cheung TT. Superior oncological outcome in laparoscopic hepatectomy for hepatocellular carcinoma, hype or hope?Hepatobiliary Surg Nutr 2017;6(6):437-438. doi: 10.21037/hbsn.2017.09.01
90. Guo I, Poon B. Prof. Simon C. Robson: “Science curiosity” is the most important element in research, as this thirst for knowledge results in new discoveries, ultimately translating to practice of clinical medicine and serving to help people. Hepatobiliary Surg Nutr 2017;6(6):439-441. doi: 10.21037/hbsn.2017.11.06
91. Jiang C, Hao C. Prof. Manuela Merli: applying knowledge into practice is important for medical students. Hepatobiliary Surg Nutr 2017;6(6):442-443. doi: 10.21037/hbsn.2017.09.04
92. Huang L, Chen W. Dream big and keep moving—the Liver, Microbiome and Academic Skills Workshop cosponsored by Hepatobiliary Surgery and Nutrition and AME Publishing Company Hepatobiliary Surg Nutr 2017;6(6):444-448. doi: 10.21037/hbsn.2017.11.07
Pulications in 2018
93. Hallet J, Mahar AL, Nathens AB, Tsang ME, Beyfuss KA, Lin Y, Coburn NG, Karanicolas PJ. The impact of perioperative blood transfusions on short-term outcomes following hepatectomy. Hepatobiliary Surg Nutr 2018;7(1):1-10. doi: 10.21037/hbsn.2017.05.0794. Wan ML, El-Nezami H. Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy. Hepatobiliary Surg Nutr 2018;7(1):11-20. doi: 10.21037/hbsn.2017.12.07
95. Zaman JA, Singh TP. The emerging role for robotics in cholecystectomy: the dawn of a new era? Hepatobiliary Surg Nutr 2018;7(1):21-28. doi: 10.21037/hbsn.2017.03.01
96. Suah A, Millis JM, Bodzin AS. Congenital membranous occlusion of the suprahepatic inferior vena cava in a pediatric liver transplant. Hepatobiliary Surg Nutr 2018;7(1):29-31. doi: 10.21037/hbsn.2017.01.05
97. Jeppsson B. Gut microbiota and surgical disease Hepatobiliary Surg Nutr 2018;7(1):32-33. doi: 10.21037/hbsn.2017.11.03
98. Elagizi A, Archer E, Lavie CJ. Behavioral primary prevention of cardiovascular diseases. Hepatobiliary Surg Nutr 2018;7(1):34-37. doi: 10.21037/hbsn.2017.12.02
99. Chen P. Enteric dysbiosis, gut barrier and liver disease Hepatobiliary Surg Nutr 2018;7(1):38-40. doi: 10.21037/hbsn.2017.12.06
100. Foerster F, Galle PR. Hepatocellular carcinoma: one world, one cancer—different guidelines?. Hepatobiliary Surg Nutr 2018;7(1):41-43. doi: 10.21037/hbsn.2018.01.05
101. Wang Q, Seki E. Astrocyte elevated gene-1 (AEG-1): a new potential therapeutic target for the treatment of nonalcoholic steatohepatitis (NASH). Hepatobiliary Surg Nutr 2018;7(1):44-47. doi: 10.21037/hbsn.2017.11.04
102. Andersen JB. Single cell profiling reveals window for immunotherapy in liver cancers Hepatobiliary Surg Nutr 20148;7(1):48-51. doi: 10.21037/hbsn.2017.12.04
103. Dewdney B, Hebbard L. A novel role for polymeric immunoglobulin receptor in tumour development: beyond mucosal immunity and into hepatic cancer cell transformation. Hepatobiliary Surg Nutr 2018;7(1):52-55. doi: 10.21037/hbsn.2017.12.05
104. Lee KF. Mirizzi syndrome: a new approach to an old problem. Hepatobiliary Surg Nutr 2018;7(1):56-57. doi: 10.21037/hbsn.2017.12.09
105. Lai Q, Mennini G. Radioembolization in the setting of liver transplantation: great expectations or hard times? Hepatobiliary Surg Nutr 2018;7(1):58-60. doi: 10.21037/hbsn.2017.12.10
106. Guo Y. The “Chinese Mode” of organ donation and transplantation: moving towards the center stage of the world. Hepatobiliary Surg Nutr 2018;7(1):61-62. doi: 10.21037/hbsn.2018.01.06
107. Blasi A, Beltran J. Comment on: Early recovery pathway for hepatectomy: data-driven liver resection care and recovery. Hepatobiliary Surg Nutr 2018;7(1):63-64. doi: 10.21037/hbsn.2017.12.08
108. Warner SG, Jutric Z, Fong Y. Response to Comment on: Early recovery pathway for hepatectomy: data-driven liver resection care and recovery. Hepatobiliary Surg Nutr 2018;7(1):65-67. doi: 10.21037/hbsn.2018.01.04
109. Cheung TT. Laparoscopic liver resection in patients with liver cirrhosis—the path towards standard of care. Hepatobiliary Surg Nutr 2018;7(1):68-69. doi: 10.21037/hbsn.2017.09.02
110. Zhou S. Dr. Morris-Stiff: the diagnosis and management of pancreatic adenocarcinoma. Hepatobiliary Surg Nutr 2018;7(1):70-72. doi: 10.21037/hbsn.2017.10.03
111. Zhao V, Li B. Prof. Sung-Gyu Lee: future perspectives of living donor liver transplantation Hepatobiliary Surg Nutr 2018;7(1):73-74. doi: 10.21037/hbsn.2017.12.12
112. Li N, Poon B, Chen G. Prof. Jamila Faivre: microbiology is a new field to me but it’s interesting. Hepatobiliary Surg Nutr 2018;7(1):75-76. doi: 10.21037/hbsn.2018.01.03
113. Melstrom LG, Warner SG, Woo Y, Sun V, Lee B, Singh G, Fong Y. Selecting incision-dominant cases for robotic liver resection: towards outpatient hepatectomy with rapid recovery. Hepatobiliary Surg Nutr 2018;7(2):77-84. doi: 10.21037/hbsn.2017.05.05
114. Coia H, Ma N, He AR, Kallakury B, Berry DL, Permaul E, Makambi KH, Fu Y, Chung FL. Detection of a lipid peroxidation-induced DNA adduct across liver disease stages. Hepatobiliary Surg Nutr 2018;7(2):85-97. doi: 10.21037/hbsn.2017.06.01
115. Cai X. Laparoscopic liver resection: the current status and the future. Hepatobiliary Surg Nutr 2018;7(2):98-104. doi: 10.21037/hbsn.2018.02.07
116. Soggiu F, Giovinazzo F, Straiton J, Turri G, Phillips J, Al-Kari B, Ahmed I, Habib M. Monosegment ALPPS hepatectomy preserving segment 4 for colorectal liver metastases: literature review and our experience. Hepatobiliary Surg Nutr 2018;7(2):105-115. doi: 10.21037/hbsn.2017.03.12
117. Castagneto Gissey L, Musleh L, Mariano G, Vennarecci G, Scotti A, Colasanti M, Meniconi RL, Campanelli A, Astudillo Diaz C, Ettorre GM. Left hepatectomy with concomitant cavo-atrial and biliary tumor thrombectomy for invasive hepatocellular carcinoma: a video report Hepatobiliary Surg Nutr 2018;7(2):116-119. doi: 10.21037/hbsn.2017.07.03
118. Huang JF, Wang HB. Do not turn sacred medicine into an ulterior political tool Hepatobiliary Surg Nutr 2018;7(2):120-121. doi: 10.21037/hbsn.2018.03.04
119. Wang P, Wu L. Hydrogen sulfide and nonalcoholic fatty liver disease. Hepatobiliary Surg Nutr 2018;7(2):122-124. doi: 10.21037/hbsn.2018.03.03
120. Pessaux P, Cherkaoui Z. Value-based healthcare: a novel approach to the evaluation of patient care. Hepatobiliary Surg Nutr 2018;7(2):125-126. doi: 10.21037/hbsn.2017.12.11
121. Gorgen A, Goldaracena N, Zhang W, Sapisochin G. Intrahepatic cholangiocarcinoma, are we making progress? Hepatobiliary Surg Nutr 2018;7(2):127-129. doi: 10.21037/hbsn.2017.12.14
122. Viganò L, Lleo A, Aghemo A. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome and hepatocellular carcinoma—a composite scenario. Hepatobiliary Surg Nutr 2018;7(2):130-133. doi: 10.21037/hbsn.2018.01.01
123. Hibi T, Sugawara Y. Locoregional therapy as a bridge to liver transplantation for hepatocellular carcinoma within Milan criteria: from a transplant oncology viewpoint. Hepatobiliary Surg Nutr 2018;7(2):134-135. doi: 10.21037/hbsn.2018.01.07
124. Kim SH, Lee EC, Park SJ. Pretransplant locoregional therapy for hepatocellular carcinoma: encouraging but insufficient. Hepatobiliary Surg Nutr 2018;7(2):136-137. doi: 10.21037/hbsn.2018.01.08
125. Armstrong MJ, Haydon G, Syn WK. Beyond the liver in patients with non-alcoholic fatty liver disease (NAFLD)—cause for concern? Hepatobiliary Surg Nutr 2018;7(2):138-142. doi: 10.21037/hbsn.2018.01.09
126. Adinolfi LE, Marrone A, Rinaldi L. Non-alcoholic fatty liver disease: beyond the liver is an emerging multifaceted systemic disease. Hepatobiliary Surg Nutr 2018;7(2):143-146. doi: 10.21037/hbsn.2018.02.01
127. Rentsch M, Schiergens TS. Treatment plan improvement by multidisciplinary case conferences for patients with colorectal cancer and synchronous liver metastases. Hepatobiliary Surg Nutr 2018;7(2):147-148. doi: 10.21037/hbsn.2018.03.05
128. Ansari D, Torén W, Andersson R. Primary lymph node ratio and hepatic resection for colorectal metastases. Hepatobiliary Surg Nutr 2018;7(2):149-150. doi: 10.21037/hbsn.2018.02.05
129. Chiang JY. The gut’s feeling on bile acid signaling in NAFLD. Hepatobiliary Surg Nutr 2018;7(2):151-153. doi: 10.21037/hbsn.2018.01.02
130. Panaro F, Testa G. Use of robotics in liver donor right hepatectomy. Hepatobiliary Surg Nutr 2018;7(2):154-155. doi: 10.21037/hbsn.2018.02.04
131. Wang J, Liu L. Prophylactic antibiotics and abdominal drainage in early recovery pathway for hepatectomy. Hepatobiliary Surg Nutr 2018;7(2):156-157. doi: 10.21037/hbsn.2018.03.09
132. Xu EC. Prof. Wei Tang—biomarkers: evaluation of early diagnosis and prognosis for patients with hepatocellular carcinoma. Hepatobiliary Surg Nutr 2018;7(2):158-160. doi: 10.21037/hbsn.2017.12.13
133. Panaro F, Benedetti E, Pineton de Chambrun G, Habibeh H, Leon P, Bouyabrine H, Herrero A, Navarro F. Indocyanine green fluorescence angiography during liver and pancreas transplantation: a tool to integrate perfusion statement’s evaluation. Hepatobiliary Surg Nutr 2018;7(3):161- 166. doi: 10.21037/hbsn.2017.07.02
134. Goja S, Yadav SK, Yadav A, Piplani T, Rastogi A, Bhangui P, Saigal S, Soin AS. Accuracy of preoperative CT liver volumetry in living donor hepatectomy and its clinical implications. Hepatobiliary Surg Nutr 2018;7(3):167-174. doi: 10.21037/hbsn.2017.08.02
135. Omagari K, Suruga K, Kyogoku A, Nakamura S, Sakamoto A, Nishioka S, Ichimura M, Miyata Y, Tajima K, Tsuneyama K, Tanaka K. A fermented mixed tea made with camellia (Camellia japonica) and third-crop green tea leaves prevents nonalcoholic steatohepatitis in Sprague-Dawley rats fed a high-fat and high-cholesterol diet. Hepatobiliary Surg Nutr 2018;7(3):175-184. doi: 10.21037/hbsn.2017.08.03
136. Lee KF, Fung AK, Lok HT, Fong AK, Chong CC, Lai PB. Robot-assisted minimally invasive procedures for complicated biliary stone disease Hepatobiliary Surg Nutr 2018;7(3):185-188. doi: 10.21037/hbsn.2017.05.12
137. Gao R, Qin H. Fluid balance in major abdominal surgery deserves more exploration. Hepatobiliary Surg Nutr 2018;7(3):189-191. doi: 10.21037/hbsn.2018.06.04
138. Giorgio A, Gatti P, Matteucci P, Giorgio V. Ablative therapies for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2018;7(3):192-194. doi: 10.21037/hbsn.2018.02.06
139. Caruso S, Patriti A, Ceccarelli G, Coratti A. Minimally invasive liver resection: has the time come to consider robotics a valid assistance?. Hepatobiliary Surg Nutr 2018;7(3):195-198. doi: 10.21037/hbsn.2018.02.02
140. Benmassaoud A, Tsochatzis EA. Loco-regional treatments on the liver transplant waiting list: unmasking hepatocellular carcinoma (HCC) biology. Hepatobiliary Surg Nutr 2018;7(3):199-201. doi: 10.21037/hbsn.2018.02.03
141. Sangiovanni A, Colombo M. Bridging to liver transplantation patients with a hepatocellular carcinoma within Milan criteria: how worth is it? Hepatobiliary Surg Nutr 2018;7(3):202-205. doi: 10.21037/hbsn.2018.03.12
142. Brudvik KW, Søreide K. Association between the lymph node ratio and hepatic tumor burden: importance for resectable colorectal liver metastases?. Hepatobiliary Surg Nutr 2018;7(3):206-208. doi: 10.21037/hbsn.2018.03.02
143. Galmozzi E, D’Ambrosio R. Nonalcoholic fatty liver disease: is the IFNL4 rs368234815 variant protective from liver damage? Hepatobiliary Surg Nutr 2018;7(3):209-211. doi: 10.21037/hbsn.2018.03.06
144. Kodali S, Singal AK. Potent suppression of hepatitis B virus and hepatocellular carcinoma: how long is good enough? Hepatobiliary Surg Nutr 2018;7(3):212-213. doi: 10.21037/hbsn.2018.03.07
145. Ishikawa T. Prevention of post-embolization syndrome after transarterial chemoembolization for hepatocellular carcinoma—is prophylactic dexamethasone useful, or not?. Hepatobiliary Surg Nutr 2018;7(3):214-216. doi: 10.21037/hbsn.2018.03.08
146. Morrison B, Kelliher L, Jones C. Enhanced recovery for liver resection—early recovery pathway for hepatectomy: data-driven liver resection care and recovery. Hepatobiliary Surg Nutr 2018;7(3):217-220. doi: 10.21037/hbsn.2018.03.13.
147. Xie F, Feng S, Sun L, Mao Y. The first-line treatment for unresectable hepatocellular carcinoma patients: lenvatinib versus sorafenib, or beyond? Hepatobiliary Surg Nutr 2018;7(3):221-224. doi: 10.21037/hbsn.2018.06.06.
148. Qiu Y, Yan X. Restrictive versus liberal fluid therapy for major abdominal surgery: is the evidence strong? Hepatobiliary Surg Nutr 2018;7(3):225-226. doi: 10.21037/hbsn.2018.06.05
149. Eng OS. Fluids in abdominal surgery: what is the goal? Hepatobiliary Surg Nutr 2018;7(3):227-228. doi: 10.21037/hbsn.2018.06.07.
150. Gruttadauria S, Pagano D. Exploring new trends in living related liver transplantation Hepatobiliary Surg Nutr 2018;7(3):229-230. doi: 10.21037/hbsn.2018.03.15.
151. Di Benedetto F, Magistri P, Halazun KJ. Use of robotics in liver donor right hepatectomy Hepatobiliary Surg Nutr 2018;7(3):231-232. doi: 10.21037/hbsn.2018.03.10.
152. Brudvik KW, Røsok B, Naresh U, Yaqub S, Fretland ÅA, Labori KJ, Edwin B, Bjørnbeth BA. Survival after resection of colorectal liver metastases in octogenarians and sexagenarians compared to their respective age-matched national population. Hepatobiliary Surg Nutr 2018;7(4):234-241. doi: 10.21037/hbsn.2017.09.03.
153. Howard C, Clements TW, Edwards JP, MacLean AR, Buie WD, Dixon E, Grondin SC, Gomes A, McColl M, Cleary SP, Jayaraman S, Daigle R, Ball CG. Synchronous colorectal liver metastases: a national survey of surgeon opinions on simultaneous resection and multidisciplinary cooperation. Hepatobiliary Surg Nutr 2018;7(4):242-250. doi: 10.21037/hbsn.2017.12.01
154. Ma WJ, Wu ZR, Shrestha A, Yang Q, Hu HJ, Wang JK, Liu F, Zhou RX, Li QS, Li FY. Effectiveness of additional resection of the invasive cancer-positive proximal bile duct margin in cases of hilar cholangiocarcinoma Hepatobiliary Surg Nutr 2018;7(4):251-269. doi: 10.21037/hbsn.2018.03.14
155. Beal EW, Tumin D, Moris D, Zhang XF, Chakedis J, Dilhoff M, Schmidt CM, Pawlik TM. Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2018;7(4):270-276. doi: 10.21037/hbsn.2018.03.16
156. Jia C, Li H, Wen N, Chen J, Wei Y, Li B. Laparoscopic liver resection: a review of current indications and surgical techniques. Hepatobiliary Surg Nutr 2018;7(4):277-288. doi: 10.21037/hbsn.2018.03.01
157. Heinrich S. Neoadjuvant therapy for pancreatic ductal adenocarcinoma—real effects or patient selection? Hepatobiliary Surg Nutr 2018;7(4):289-291. doi: 10.21037/hbsn.2018.03.11
158. Yoneda M, Imajo K, Nakajima A. Will the magnetic resonance imaging proton density fat fraction replace liver biopsy as the gold standard for detecting steatosis? Hepatobiliary Surg Nutr 2018;7(4):292-293. doi: 10.21037/hbsn.2018.04.02
159. Cucchetti A, Serenari M. Efficacy of radiofrequency ablation of hepatocellular carcinoma prior to liver transplantation and the need for competing-risk analysis. Hepatobiliary Surg Nutr 2018;7(4):294-296. doi: 10.21037/hbsn.2018.04.05
160. Finn RS. Searching for common ground in a global disease. Hepatobiliary Surg Nutr 2018;7(4):297-299. doi: 10.21037/hbsn.2018.04.06
161. Imai K, Baba H. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: is it time to reconsider the current treatment guidelines? Hepatobiliary Surg Nutr 2018;7(4):300-301. doi: 10.21037/hbsn.2018.05.02
162. ANault JC, Nahon P, Séror O. Percutaneous ablation for HCC eligible to transplantation: providing more opportunities of remission in the context of graft shortage. Hepatobiliary Surg Nutr 2018;7(4):302-304. doi: 10.21037/hbsn.2018.06.01
163. Grootveld M, Percival BC, Grootveld KL. Chronic non-communicable disease risks presented by lipid oxidation products in fried foods. Hepatobiliary Surg Nutr 2018;7(4):305-312. doi: 10.21037/hbsn.2018.04.01
164. Chen CL, Cheng YF, Ou HY, Yong CC, Lin TS, Wang SH, Lin CC, Concejero AM. Complete portal vein occlusion after cyanoacrylate sclerotherapy in biliary atresia treated by living donor liver transplantation with intraoperative portal vein stenting via segment 4 portal vein stump. Hepatobiliary Surg Nutr 2018;7(4):313-316. doi: 10.21037/hbsn.2018.04.03.
165. Ariche A, Schvimer M, Inbar Y, Dreznik Y. Adenosquamous carcinoma arising in a duplication cyst of the gallbladder. Hepatobiliary Surg Nutr 2018;7(4):317-319. doi: 10.21037/hbsn.2018.04.04.
166. Lee KF, Chong CC, Fong AK, Fung AK, Lok HT, Cheung YS, Wong J, Lai PB. Pattern of disease recurrence and its implications for postoperative surveillance after curative hepatectomy for hepatocellular carcinoma: experience from a single center. Hepatobiliary Surg Nutr 2018;7(5):320-330. doi: 10.21037/hbsn.2018.03.17.
167. Najar M, Crompot E, Raicevic G, Sokal EM, Najimi M, Lagneaux L. Cytokinome of adult-derived human liver stem/progenitor cells: immunological and inflammatory features . Hepatobiliary Surg Nutr 2018;7(5):331-344. doi: 10.21037/hbsn.2018.05.01
168. Rodriguez M, Memeo R, Leon P, Panaro F, Tzedakis S, Perotto O, Varatharajah S, de’Angelis N, Riva P, Mutter D, Navarro F, Marescaux J, Pessaux P. Which method of distal pancreatectomy is cost-effective among open, laparoscopic, or robotic surgery? Hepatobiliary Surg Nutr 2018;7(5):345-352. doi: 10.21037/hbsn.2018.09.03.
169. Wen T, Jin C, Facciorusso A, Donadon M, Han HS, Mao Y, Dai C, Cheng S, Zhang B, Peng B, Du S, Jia C, Xu F, Shi J, Sun J, Zhu P, Nara S, Millis JM. MDT of West China Hospital. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. Hepatobiliary Surg Nutr 2018;7(5):353-371. doi: 10.21037/hbsn.2018.08.01.
170. Barbara M, Scott A, Alkhouri N. New insights into genetic predisposition and novel therapeutic targets for nonalcoholic fatty liver disease. Hepatobiliary Surg Nutr 2018;7(5):372-381. doi: 10.21037/hbsn.2018.08.05.
171. Costanzo A, Rampulla V, Varricchio A, Petrelli F. The role of selective internal radiotherapy with Y-90 resin microsphere in first-line therapy for hepatic colorectal metastases. Hepatobiliary Surg Nutr 2018;7(5):382-385. doi: 10.21037/hbsn.2018.06.09.
172. Nair A, Hashimoto K. Extended criteria donors in liver transplantation—from marginality to mainstream. Hepatobiliary Surg Nutr 2018;7(5):386-388. doi: 10.21037/hbsn.2018.06.08.
173. Albhaisi S, Issa D, Alkhouri N. Non-alcoholic fatty liver disease: a pandemic disease with multisystem burden. Hepatobiliary Surg Nutr 2018;7(5):389-391. doi: 10.21037/hbsn.2018.07.01.
174. Yi NJ. Inspiration of liver resection for hepatocellular carcinoma associated with hepatic vein invasion, not inferior vena cava invasion. Hepatobiliary Surg Nutr 2018;7(5):392-394. doi: 10.21037/hbsn.2018.07.02.
175. Roselló S, Borrás R, Cervantes A. Maintenance with single agent bevacizumab fails to improve disease-control in metastatic colorectal cancer. Hepatobiliary Surg Nutr 2018;7(5):395-398. doi: 10.21037/hbsn.2018.08.02.
176. Wisniewski M, Placide PA, Granier S, Al Shatti Y, Al Qalaf S, Bouattour M, Lamuraglia M, Hammel P. Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?—review of the open label phase III trial CONKO 005. Hepatobiliary Surg Nutr 2018;7(5):399-402. doi: 10.21037/hbsn.2018.08.03.
177. Kent OA. Increased mutant KRAS gene dosage drives pancreatic cancer progression: evidence for wild-type KRAS as a tumor suppressor? Hepatobiliary Surg Nutr 2018;7(5):403-405. doi: 10.21037/hbsn.2018.07.03.
178. Ko AH. Moving from late to early stage disease: lessons learned from erlotinib in pancreatic cancer. Hepatobiliary Surg Nutr 2018;7(5):406-408. doi: 10.21037/hbsn.2018.06.02.
179. Jin S, Jiang R, Ma W. Actively implementing enteral nutrition to reduce parenteral nutrition-associated liver disease. Hepatobiliary Surg Nutr 2018;7(5):409-411. doi: 10.21037/hbsn.2018.06.03.
180. Al Hashmi AW, Panaro F, Navarro F. A “reappearance” of gallbladder in a liver transplant recipient. Hepatobiliary Surg Nutr 2018;7(5):412-413. doi: 10.21037/hbsn.2018.05.03.
181. Li B. William S. Blaner: successful researchers ought to be exceptionally motivated towards generating new knowledge. Hepatobiliary Surg Nutr 2018;7(5):414-417. doi: 10.21037/hbsn.2018.09.02.